Mark Testa
Executive vice presidentMark Testa is the executive vice president of Regenexx for Business
-
Platelet-rich plasma and bone marrow concentrate can replace the need for up to 70% of elective orthopedic surgeries.
May 24
Mark Testa is the executive vice president of Regenexx for Business
Platelet-rich plasma and bone marrow concentrate can replace the need for up to 70% of elective orthopedic surgeries.